
As cellular and bispecific immunotherapies move into earlier treatment lines, pharmacists are interpreting new guidelines, managing toxicities, and shaping patient care strategies.

As cellular and bispecific immunotherapies move into earlier treatment lines, pharmacists are interpreting new guidelines, managing toxicities, and shaping patient care strategies.